Immunocore
IMCR
Market cap $1.68B

33.50 USD

-0.41

1.21%

At close Jul 30, 4:00 PM EDT

After hours

33.50

+0.00

0.00%

1 day

-1.21%

5 days

-6.94%

1 month

6.76%

3 months

11.30%

6 months

2.73%

Year to date

12.34%

1 year

-16.44%

5 years

-22.45%

10 years

-22.45%

About: Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Employees: 493

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

88% more call options, than puts

Call options by funds: $6.54M | Put options by funds: $3.48M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]

24% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 33

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

3.68% more ownership

Funds ownership: 90.74% [Q4 2024] → 94.42% (+3.68%) [Q1 2025]

2% more funds holding

Funds holding: 113 [Q4 2024] → 115 (+2) [Q1 2025]

5% more capital invested

Capital invested by funds: $1.34B [Q4 2024] → $1.4B (+$63.4M) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$86

157%

upside

Avg. target

$93

178%

upside

High target

$100

199%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio	199%upside $100	Buy Reiterated	2 Jun 2025
Oppenheimer Jeff Jones	157%upside $86	Outperform Maintained	8 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about IMCR published over the past 30 days

Zacks Investment Research

Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The consensus price target hints at a 72.3% upside potential for Immunocore (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Zacks Investment Research

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by Immunocore (Nasdaq: IMCR) as the distribution and commercialization partner for KIMMTRAK, for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in Turkey and across the Middle East, North Africa, Caucasus and the Commonwealth of Independent States (CIS) regions. Immunocore is a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases.

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

Zacks Investment Research

Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 65.2% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet

Immunocore to present at the 2025 Jefferies Global Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

Immunocore to present at the 2025 Jefferies Global Healthcare Conference

Zacks Investment Research

Is it a Good Idea to Invest in Immunocore Stock Right Now?

IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.

Is it a Good Idea to Invest in Immunocore Stock Right Now?

Zacks Investment Research

Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Zacks Investment Research

New Strong Buy Stocks for May 8th

BTSG, NWFL, MNRO, UBSI and IMCR have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2025.

New Strong Buy Stocks for May 8th

Zacks Investment Research

Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics

The headline numbers for Immunocore (IMCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics

Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

Immunocore reports first quarter financial results and provides a business update

See News Rankings

Charts implemented using Lightweight Charts™